Phase 3 progress for Universal Flu vaccine

Israel’s BiondVax has 12,400 participants from 83 hospitals in the Phase 3 double-blind placebo-controlled trials of its Universal Flu vaccine. If successful, the new vaccine could reach pharmacies in 2023. BiondVax’s new Jerusalem facility can produce 20-40 million doses per year.,7340,L-3775594,00.html

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *